By Ben Stevens, BusinessCann.com, August 3, 2022

"STENOCARE has seen double digit price rises across both the Copenhagen NASDAQ and the Frankfurt Stock Exchange, jumping 17.5% and 10% respectively over the past week.

This recent uptick follows three months of consistent share price declines for the Danish medical cannabis oil producer, an experience shared amongst the majority of its European peers.

While this ongoing downturn in European cannabis stocks has forced many cannabis companies into near dormancy, Stenocare plans to ramp up its momentum of growth even further.

Its CEO Thomas Skovlund Schnegelsberg told BusinessCann: "The way that we look at it now is the opportunity. Competition is struggling, all of the North American companies are scaling down or even exiting. So that leaves a great spot for a company like Stenocare.

"We are building momentum here and we certainly don't want to lose that. You'll probably see us become even more aggressive in our ambitions."

Read more:

(businesscann.com)

Stenocare har en betalt digital IR-aftale med Proinvestor.com